ATE377081T1 - Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren - Google Patents
Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatorenInfo
- Publication number
- ATE377081T1 ATE377081T1 AT01914501T AT01914501T ATE377081T1 AT E377081 T1 ATE377081 T1 AT E377081T1 AT 01914501 T AT01914501 T AT 01914501T AT 01914501 T AT01914501 T AT 01914501T AT E377081 T1 ATE377081 T1 AT E377081T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- polypeptides
- growth factors
- dothelial
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18520500P | 2000-02-25 | 2000-02-25 | |
US20533100P | 2000-05-18 | 2000-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE377081T1 true ATE377081T1 (de) | 2007-11-15 |
Family
ID=26880920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01914501T ATE377081T1 (de) | 2000-02-25 | 2001-02-26 | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren |
Country Status (8)
Country | Link |
---|---|
US (5) | US6965010B2 (de) |
EP (1) | EP1259626B1 (de) |
JP (1) | JP4981229B2 (de) |
AT (1) | ATE377081T1 (de) |
AU (3) | AU3988401A (de) |
CA (1) | CA2400948A1 (de) |
DE (1) | DE60131146T2 (de) |
WO (1) | WO2001062942A2 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060950A2 (en) * | 1994-11-14 | 2002-08-08 | Ludwig Institute For Cancer Research | Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
EP1183357A2 (de) * | 1999-05-20 | 2002-03-06 | Scios Inc. | Vaskuläre endothelzellen wachstumsfaktordimere |
US7167615B1 (en) | 1999-11-05 | 2007-01-23 | Board Of Regents, The University Of Texas System | Resonant waveguide-grating filters and sensors and methods for making and using same |
EP1259626B1 (de) * | 2000-02-25 | 2007-10-31 | Ludwig Institute For Cancer Research | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren |
EP1289565B1 (de) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Arzneimitteln zur zielgerichtung von endothelzellen |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
WO2002014367A1 (fr) * | 2000-08-10 | 2002-02-21 | Center For Advanced Science And Technology Incubation,Ltd. | Facteur de croissance chimere de cellules endotheliales vasculaires de type humain |
US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
EP1399484B1 (de) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Doppelspezifischer ligand und dessen verwendung |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
EP1551227A4 (de) * | 2002-05-03 | 2006-05-17 | Ludwig Inst Cancer Res | Verhinderung eines sekundären lymphödems mit vegf-d-dna |
CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
EP1603935A4 (de) | 2003-03-03 | 2007-03-21 | Dyax Corp | SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG |
EP1635860A2 (de) * | 2003-06-12 | 2006-03-22 | Ludwig Institute For Cancer Research | Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie |
WO2005016963A2 (en) * | 2003-06-12 | 2005-02-24 | Ludwig Institute For Cancer Research | Heparin binding veger-3 ligands |
US7422741B2 (en) | 2004-03-05 | 2008-09-09 | Vegenics Limited | VEGFR-3 fusion proteins |
US7476654B2 (en) * | 2004-03-08 | 2009-01-13 | Ludwig Institute For Cancer Research | Method for modulating, regulating and/or stabilizing angiogenesis |
EP2412816B1 (de) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Verfahren zur verbesserten Proteinexpression durch Strain-Engineering |
US7553496B2 (en) * | 2004-12-21 | 2009-06-30 | University Of Kentucky Research Foundation | VEGF-A as an inhibitor of angiogenesis and methods of using same |
JP2008537752A (ja) * | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法 |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット |
WO2007089780A2 (en) * | 2006-01-30 | 2007-08-09 | Licentia, Ltd. | Bmx/etk tyrosine kinase gene therapy materials and methods |
CN1903880B (zh) * | 2006-08-02 | 2010-05-12 | 中国人民解放军军事医学科学院基础医学研究所 | 抗肿瘤血管内皮生长因子vegf-e抗原及其编码基因与应用 |
WO2008096268A2 (en) * | 2007-02-07 | 2008-08-14 | Vegenics Limited | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
MX2009011523A (es) | 2007-04-27 | 2009-11-09 | Dow Global Technologies Inc | Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas. |
MX2009012968A (es) | 2007-06-06 | 2010-04-01 | Domantis Ltd | Polipeptidos, dominios variables de anticuerpo y antagonistas. |
US20110305703A1 (en) * | 2008-12-08 | 2011-12-15 | Vegenics Pty Limited | Isolated vegf-c and vegf-d peptides and uses thereof |
WO2011154308A1 (en) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | New compositions and cell therapy methods for the treatment of cirrhosis |
WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
WO2014081772A1 (en) * | 2012-11-20 | 2014-05-30 | Albert Einstein College Of Medicine Of Yeshiva University | Regeneration of coronary artery by coronary endothelial specific progenitor cells |
WO2014124487A1 (en) | 2013-02-18 | 2014-08-21 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
TW201506036A (zh) * | 2013-08-14 | 2015-02-16 | Laurantis Pharma Oy | Vegf-c及ccbe1之治療用途 |
US20180111972A1 (en) * | 2015-01-16 | 2018-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Hybrid chimera polypeptides as dual inhibitors of vascular endothelial growth factor receptor and platelet-derived growth factor receptor |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) * | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4227427A (en) * | 1977-09-08 | 1980-10-14 | Dana Corporation | Drive unit assembly |
US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US5498600A (en) * | 1984-10-12 | 1996-03-12 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US5037630A (en) * | 1985-01-14 | 1991-08-06 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US5087244A (en) * | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5955291A (en) | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
ES2298325T3 (es) * | 1992-03-13 | 2008-05-16 | Biomerieux B.V. | Peptidos y secuencias de acido nucleico relacionadas con el virus epstein barr. |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
DE69326631T2 (de) * | 1992-03-19 | 2000-06-08 | Medtronic Inc | Intraluminales Erweiterungsgerät |
US5879934A (en) * | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US6107046A (en) | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
US5776755A (en) | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
US5336178A (en) * | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5661033A (en) * | 1992-11-25 | 1997-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Gene transfer using herpes virus vectors as a tool for neuroprotection |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5834441A (en) * | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
EP0733103B1 (de) * | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Die erzielung hoher titer des rekombinanten aav-vektors |
FR2716682B1 (fr) * | 1994-01-28 | 1996-04-26 | Centre Nat Rech Scient | Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations. |
CN1267550C (zh) | 1994-03-08 | 2006-08-02 | 人体基因组科学有限公司 | 血管内皮生长因子2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US6130071A (en) | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
US6221839B1 (en) | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6245530B1 (en) | 1995-08-01 | 2001-06-12 | Ludwig Institute For Cancer Research | Receptor ligand |
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US5607918A (en) | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
FR2732357B1 (fr) | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
US5773289A (en) * | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US5622856A (en) * | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
EP0848755B2 (de) | 1995-09-08 | 2011-02-09 | Genentech, Inc. | Vegf-verwandtes protein |
ES2239338T5 (es) | 1995-09-29 | 2013-05-31 | Vegenics Pty Ltd | Genes regulados y sus usos |
US5653689A (en) * | 1995-09-30 | 1997-08-05 | Abacus Design & Development, Inc. | Infusion catheter |
US5830727A (en) * | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5785965A (en) | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
AU733322B2 (en) | 1996-07-15 | 2001-05-10 | Chugai Seiyaku Kabushiki Kaisha | Novel VEGF-like factor |
EP1749836B1 (de) | 1996-08-23 | 2009-06-17 | Vegenics Limited | Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D) |
PL189744B1 (pl) | 1996-11-01 | 2005-09-30 | Eurogene Ltd | Zastosowanie środka będącego białkiem VEGF oraz wszczep do stosowania leczniczego |
US6172043B1 (en) * | 1997-01-10 | 2001-01-09 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides |
WO1999030157A2 (en) | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Neuropilins in methods for diagnosis and prognosis of cancer |
CN1345247A (zh) | 1997-12-24 | 2002-04-17 | 路德维格癌症研究所 | 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法 |
NZ511408A (en) | 1998-10-09 | 2004-04-30 | Licentia Ltd | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
CN1338943A (zh) | 1998-10-26 | 2002-03-06 | 路德维格癌症研究院 | 利用vegf-c或vegf-d基因或蛋白预防再狭窄 |
JP2003517275A (ja) | 1998-11-02 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 哺乳動物vegfレセプター−2に結合し、これを活性化するオルフウイルスnz2由来の血管内皮細胞増殖因子様タンパク質 |
ES2259247T3 (es) | 1998-12-21 | 2006-09-16 | Ludwig Institute For Cancer Research | Anticuerpos frente a vegf-d truncado y sus usos. |
EP1156820B1 (de) | 1999-02-08 | 2008-07-09 | Human Genome Sciences, Inc. | Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) |
WO2001012669A1 (en) | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
EP1259626B1 (de) * | 2000-02-25 | 2007-10-31 | Ludwig Institute For Cancer Research | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren |
AU2001264565B2 (en) | 2000-05-03 | 2006-12-07 | Vegenics Limited | A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
US20030211988A1 (en) | 2001-01-09 | 2003-11-13 | Epstein Stephen E | Enhancing lymph channel development and treatment of lymphatic obstructive disease |
WO2005016963A2 (en) | 2003-06-12 | 2005-02-24 | Ludwig Institute For Cancer Research | Heparin binding veger-3 ligands |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
-
2001
- 2001-02-26 EP EP01914501A patent/EP1259626B1/de not_active Expired - Lifetime
- 2001-02-26 CA CA002400948A patent/CA2400948A1/en not_active Abandoned
- 2001-02-26 AU AU3988401A patent/AU3988401A/xx active Pending
- 2001-02-26 DE DE60131146T patent/DE60131146T2/de not_active Expired - Lifetime
- 2001-02-26 AT AT01914501T patent/ATE377081T1/de not_active IP Right Cessation
- 2001-02-26 AU AU2001239884A patent/AU2001239884B2/en not_active Ceased
- 2001-02-26 JP JP2001561752A patent/JP4981229B2/ja not_active Expired - Fee Related
- 2001-02-26 WO PCT/US2001/006113 patent/WO2001062942A2/en active IP Right Grant
- 2001-02-26 US US09/795,006 patent/US6965010B2/en not_active Expired - Fee Related
-
2005
- 2005-02-24 US US11/064,774 patent/US7309604B2/en not_active Expired - Fee Related
-
2006
- 2006-11-10 AU AU2006235995A patent/AU2006235995A1/en not_active Abandoned
-
2007
- 2007-08-28 US US11/846,337 patent/US7566566B2/en not_active Expired - Fee Related
-
2009
- 2009-04-10 US US12/422,048 patent/US7902149B2/en not_active Expired - Fee Related
-
2011
- 2011-01-28 US US13/016,728 patent/US8278098B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110207664A1 (en) | 2011-08-25 |
US20090318352A1 (en) | 2009-12-24 |
US20020151680A1 (en) | 2002-10-17 |
AU2001239884C1 (en) | 2001-09-03 |
US7309604B2 (en) | 2007-12-18 |
AU3988401A (en) | 2001-09-03 |
US7566566B2 (en) | 2009-07-28 |
US7902149B2 (en) | 2011-03-08 |
WO2001062942A2 (en) | 2001-08-30 |
EP1259626A2 (de) | 2002-11-27 |
US8278098B2 (en) | 2012-10-02 |
AU2001239884B2 (en) | 2006-08-10 |
US6965010B2 (en) | 2005-11-15 |
US20080058263A1 (en) | 2008-03-06 |
WO2001062942A3 (en) | 2002-03-21 |
JP2004507208A (ja) | 2004-03-11 |
JP4981229B2 (ja) | 2012-07-18 |
DE60131146D1 (de) | 2007-12-13 |
AU2006235995A1 (en) | 2006-12-07 |
DE60131146T2 (de) | 2008-03-06 |
US20050267024A1 (en) | 2005-12-01 |
CA2400948A1 (en) | 2001-08-30 |
EP1259626B1 (de) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE377081T1 (de) | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren | |
DE69637570D1 (de) | Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung | |
ATE507240T1 (de) | Materialien und verfahren für wachstumsfaktorbindende konstrukte | |
DE69629181D1 (de) | Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen | |
DE60034957D1 (de) | Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2-familie exprimieren | |
BR0209933A (pt) | Uso de um ativador da transmembrana e modulador de cálcio, e proteìna de fusão de (taci) - imunoglobulina interatuadora do ligando da ciclofilina, proteìna de fusão, molécula de ácido nucleico, e, composição farmacêutica | |
IL210392A0 (en) | Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof | |
ATE554784T1 (de) | Hochaffiner ligand für p75 neurotrophin-rezeptor | |
BR9611428A (pt) | Formação e uso complexos de proteìnas de priÈnio (prp) | |
IS8016A (is) | Prótín sem bindast viðtaka NOGO | |
UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
EP2316944A3 (de) | Bindungsreagenzien: chimäre Ligand/Rezeptorproteine | |
WO2003076592A3 (en) | Novel method for delivery and intracellular synthesis of sirna molecules | |
PL378566A1 (pl) | Ligandy dla białek wiążących TGF-beta i ich zastosowania | |
TW200716746A (en) | Methods for identifying a compound modulating the binding between polypeptides | |
IL144247A0 (en) | Novel odorant receptors in drosophila | |
WO1994026891A3 (en) | Purified mammalian flt3 ligands and agonists and antagonists thereof | |
AU1218202A (en) | Receptor in the ED<sub>b</sub> fibronectin domain | |
DE69402177D1 (de) | Synthese von dimer-blöcken und ihre verwendung bei der zusammensetzung von oligonukleotiden | |
TR200003695T2 (tr) | Anjiyostatin bağlayıcı protein. | |
ATE359263T1 (de) | Substitutierte aminosaeuren als erythropoietin- mimetica | |
ATE420162T1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
WO2000040604A3 (en) | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | |
EP1568770A3 (de) | Pharmazeutische Verwendung von Verbindungen die einen "trace amine" Rezeptor aus Säugetiere binden | |
WO2001021794A3 (en) | Smad associating polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |